Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. PharmaKon Pharmaceuticals
WARNING LETTER
•PharmaKon Pharmaceuticals•April 8, 2014

PharmaKon Pharmaceuticals – FDA Warning Letter, Apr 8, 2014

Record Details

On May 21, 2015, the FDA issued a Warning Letter to Pharmakon Pharmaceuticals, an outsourcing facility, following inspections from March 5-13, 2014, and April 2-8, 2014. The second inspection was prompted by adverse event reports of over-sedation in infants due to incorrectly concentrated midazolam.

The FDA identified serious deficiencies in sterile drug production, leading to adulterated and misbranded products. Violations included insanitary conditions (e.g., technicians touching non-sterile surfaces then performing aseptic manipulations without re-disinfecting gloves), failure to demonstrate adequate ISO 5 area protection, and significant Current Good Manufacturing Practice (CGMP) violations. Specific CGMP failures included inadequate labeling material examination, lack of validated aseptic and sterilization procedures, insufficient equipment maintenance for aseptic conditions, improper personnel clothing, inadequate cleaning/disinfection systems, insufficient environmental monitoring, and lack of final product conformance testing for sterile batches.

Additionally, midazolam injection products were found to be super-potent (180.4% and 187.3% of declared concentration), violating USP standards and rendering them adulterated under FDCA section 501(b). The facility also failed to meet 503B outsourcing facility conditions, such as incomplete labeling (missing address, phone, dosage form, "This is a compounded drug" statement, and inactive ingredients) and failure to submit

Company
PharmaKon Pharmaceuticals
Inspection date
April 8, 2014
Product type
Drugs
Office
Detroit District Office
People
  • Art O. Czabaniuk (Program Division Director)
  • Tina M. Pawlowski (Compliance Officer)
View Company Profile

ID · d3e7207c-7245-4a7b-b13e-62088aa9d3f8

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 351(a)(2)(B)21 U.S.C. 353b21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 360eee-121 U.S.C. 351(a)(2)(A)21 CFR 21021 CFR 21121 U.S.C. 351(b)

Full citation text and observation details available on the Dashboard.

Other documents for PharmaKon Pharmaceuticals
  • 483 - 2014-04-08April 8, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore PharmaKon Pharmaceuticals
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.